ELC partners with Serpin Pharma for skin care innovation

NEW YORK - The Estée Lauder Companies Inc. (NYSE: EL), a global leader in prestige beauty with a market capitalization of $26.9 billion, has announced an exclusive partnership with biotechnology company Serpin Pharma. According to InvestingPro analysis, the company is currently trading below its Fair Value, suggesting potential upside opportunity despite recent market challenges. The collaboration is set to leverage Serpin Pharma’s extensive research on anti-inflammatory processes to potentially develop new skin care products.

The partnership will focus on integrating proprietary biotech technology from Serpin Pharma, which has shown effectiveness in reducing inflammation and enhancing cell resilience. By tapping into a specific superfamily of proteins known as SERPINs (Serine Protease Inhibitors), the companies aim to create cosmetic solutions that address skin irritation, aging, and sensitivity. This innovation drive comes as ELC maintains impressive gross profit margins of 73.15%, demonstrating strong pricing power in its premium beauty segment.

Carl Haney, Executive Vice President of Global Innovation and R&D at The Estée Lauder Companies, highlighted the partnership’s potential to push the boundaries of scientific discovery and provide rapid relief for skin irritation and sensitivity for their customers. Cohava Gelber, PhD, MBA, CEO of Serpin Pharma, expressed pride in the collaboration, emphasizing the innovative approach of using the body’s natural mechanisms to resolve inflammation.

The initiative is part of ELC’s strategic vision, Beauty Reimagined, which includes a commitment to transformative product innovation. The company’s R&D efforts are supported by a global network of innovation centers and a multidisciplinary team with expertise in various scientific fields.

This collaboration builds upon ELC’s longstanding expertise in longevity science, biotechnology, and fermentation, as well as its history of partnering with biotech companies to commercialize breakthrough technologies.

The Estée Lauder Companies’ portfolio includes numerous esteemed brands, and its products are available in around 150 countries. While the company has maintained dividend payments for 30 consecutive years, recent financial data shows temporary profitability challenges, though analysts predict a return to profitability this year. Serpin Pharma, on the other hand, is a clinical-stage company focusing on anti-inflammatory and immune-modulating therapies and has developed a peptide therapeutic with significant anti-inflammatory and regenerative properties.

This partnership represents a significant step in ELC’s ongoing efforts to innovate within the skin care sector, aiming to deliver cutting-edge solutions to consumers worldwide. The information for this article is based on a press release statement.

In other recent news, Estee Lauder (NYSE:EL) reported a 6% decrease in net sales for the second quarter of fiscal 2025, with declines in skincare, hair care, and makeup not offset by a slight growth in fragrance. Despite surpassing earnings expectations with an adjusted EPS of $0.62, the company’s cautious outlook for upcoming quarters has raised concerns among investors. Estee Lauder’s travel retail segment, once highly profitable, continues to face challenges, particularly in the Asia Pacific region. In response to these ongoing issues, Estee Lauder has announced significant restructuring efforts, including potential job cuts totaling up to 7,000 positions.

S&P Global Ratings downgraded Estee Lauder’s credit rating due to a prolonged business recovery, particularly in Asia, and expects leverage to remain high in the coming years. Meanwhile, DA Davidson maintained its Buy rating for Estee Lauder, with a price target of $81, citing the company’s strategic efforts to become leaner and more agile. However, Stifel and Canaccord Genuity both lowered their price targets to $77 and $70, respectively, while maintaining a Hold rating, reflecting concerns over the company’s turnaround efforts and market pressures.

Estee Lauder’s management has introduced a strategic initiative titled "Beauty Reimagined" to address these challenges, focusing on innovation, channel expansion, and operational efficiencies. Despite these efforts, analysts remain cautious, noting persistent external pressures and uncertainties in key markets like China and Korea. The company’s outlook remains negative, with the possibility of further ratings downgrades if performance does not improve.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.